Myasthenia gravis refers to a neurological condition caused due to the presence of autoimmune diseases. The treatment procedures usually encompass medications, plasmapheresis and surgical removal of the thymus. This condition has been prevalently observed in female casualties below the age of 40 and male casualties above the age of 60. Swift action medications are available in the market which has advantageously helped the market growth rate of the drugs used in the treatment of this condition. Surgical procedures are applicable for victims who are assessed with the presence of thymomas and cancerous tissues. Medications will not be helpful in such cases. Patients who had gotten diagnosed with this particular condition are susceptible for various symptoms that include exercise induced fatigue and consistent weakness. Drugs like acetylcholinesterase inhibitors resolve issues related to muscle functioning whilst immunosuppressant drugs minimize the effects of autoimmune process. Drugs like atropine, prednisone (a steroid drug) and pyridostigmine have been rampantly used in the market for the treatment of this condition.
Market value of myasthenia gravis drugs:
Market analysts have reported that the global market value of myasthenia gravis drugs industry will grow to a considerable extent with significant Cumulative Average Growth Rate (CAGR) percent in the impending years. The major market driver is the inordinate increase in diseased geriatric population. Asian pacific countries have experienced consistent expansion in terms of growth; however this also entails the rapid growth in the rate of diseased population. Consequently, this region exhorts heavy market growth. The market is dominated by North American countries due to the inception of new innovative drug formulations, expanded space for government funded research centers and favorable regulations and policies passed by government. The market is dominated by anticholinesterases in terms of drug usage for treatment. This is immediately followed by the usage of immunosuppressant drugs and intravenous immune globulins.
The usage of anticholinesterases for the treatment procedure of myasthenia gravis involves lesser long-term side effects and swift action. Pyridostigmine bromide is the most commonly used drug in the category of anticholinesterases. On the other hand, immunosuppressant drugs suppress the production of detrimental antibodies that cause myasthenia gravis. Drugs of this category include monoclonal antibodies, Imuran, CellCept, Prograf, prednisone and Trexall. The usage of immunosuppressant drugs often leads to the destruction of good antibodies. Consequently, patients become susceptible for other infectious conditions due to the lowering of immunity. Drugs like Gamimune and Gammagard fall under the category of intravenous immune globulins that aid in fast recovery for the cases of rapidly worsening myasthenia gravis.
The market of this sector will generate high revenue yield in the impending years due to the pervasiveness of diseased population.